ACTG 265--LIVE ATTENTUATED VARICELLA VACCINE IN HIV INFECTION CHILDREN

ACTG 265——针对艾滋病毒感染儿童的减毒水痘活疫苗

• 批准号: 6219837
• 负责人: Stuart E Starr
• 金额: $ 0.06万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219837
• 关键词: AIDS therapy; AIDS vaccines; HIV infections; attenuated microorganism; child (0-11); clinical research; clinical trials; human subject; human therapy evaluation; live vaccine; pediatric AIDS; varicella zoster virus; viral vaccines

ACTG 265 is a controlled study of the safety and efficacy of two doses of live attenuated varicella vaccine in asymptomatic or mildly symptomatic children with HIV infection. The treatment arm of this study closed to accrual of patients in March 1998; the control arm closed to accrual in July 1998. All study subjects will be followed for 3 years. Varicella vaccine was safe in this patient population.

ACTG 265是一项在无症状或轻度症状的HIV感染儿童中进行的两剂水痘减毒活疫苗安全性和有效性的对照研究。 本研究的治疗组于1998年3月结束招募患者;对照组于1998年7月结束招募。 将对所有研究受试者进行3年随访。 水痘疫苗在该患者人群中是安全的。